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ABSTRACT

Background: Esophageal carcinoma is an aggressive disease that is often treated with
neoadjuvant therapy followed by surgical resection. Diabetes mellitus (DM) has been
associated with reduced efficacy of chemoradiation (CRT) in other gastrointestinal
cancers. The goal of this study was to determine if DM affects response to neoadjuvant
CRT in the management of gastroesophageal carcinoma.
Methods: We retrospectively reviewed the esophageal cancer patient databases and
subsequently analyzed those patients who received neoadjuvant CRT followed by
surgical resection at two institutions, Thomas Jefferson University (TJUH) and Fox
Chase Cancer Center (FCCC). Comparative analyses of rates of pathologic complete
response rate (pCR) and pathologic downstaging in DM patients versus non-DM patients
was performed.
Results: Two hundred and sixty patients were included in the study; 36 patients had DM
and 224 were non-diabetics. The average age of the patients was 61 years (range 24-84
years). The overall pCR was 26%. The pCR rate was 19% and 27% for patients with
DM and without DM, respectively (p= 0.31). Pathologic downstaging occurred in 39%
of study patients, including of 33% of DM patients and 40% of non-DM patients
(p=0.42).

Conclusions: Although the current analysis does not demonstrate a significant reduction
in pCR rates or pathologic downstaging in patients with DM, the observed trend suggests
that a potential difference may be observed with a larger patient population. Further
studies are warranted to evaluate the influence of DM on the effectiveness of neoadjuvant
CRT in esophageal cancer.
INTRODUCTION
Over the past two decades, diabetes mellitus (DM) has become endemic
throughout the United States and globally. It is estimated that by the year 2010, 221
million people will be affected with diabetes; up from 124 million in 1997 1. Because an
increasing number of cancer patients will also carry the diagnoses of DM, it is important
to fully understand the implications that DM has on the prognosis and treatment of cancer
treatment.
In 2004, Coughlin et al, in a large prospective cohort study, found that diabetes
mellitus was an independent predictor of mortality from multiple cancers, including
cancer of the colon, breast, liver, pancreas, and bladder. Diabetes is often considered to
be a common risk factor for esophageal adenocarcinoma. A recent meta-analyses
comparing overall survival in all cancer patients with and without preexisting diabetes
found that diabetic patients are at an increased risk for long-term, all-cause mortality
compared with non-diabetic patients 2.
Esophageal cancer is the eighth most common cause of cancer worldwide 3. It
often presents at an advanced stage and therefore tends to be incurable. For resectable
disease, surgery is the gold standard treatment. Even with improving resection rates and
decreasing postoperative mortality rates, 5-year survival after esophagectomy is only 25-

35% 3-6. Neoadjuvant chemotherapy and radiation therapy are often added to the
treatment of patients with resectable esophageal cancer, although the benefits remain
small 7-9.
Response to neoadjuvant therapy is a valuable marker of tumor biology and
prognosis. Numerous studies have shown that the subset of esophageal cancer patients
that are able to achieve a complete pathologic response (pCR) after neoadjuvant therapy
have significantly better outcomes 10-14 . It is therefore imperative to determine if there
are any patient related factors that may affect individual ability to achieve pCR. In 2008,
Caudle et al demonstrated that although diabetic patients had a similar rate of
downstaging after neoadjuvant therapy compared to non-diabetics, no diabetic patients
achieved a pCR. The authors concluded that neoadjuvant therapy in rectal cancer is less
effective in diabetic patients than in non-diabetic patients. The goal of the current study
was to determine if diabetes mellitus had an influence on the rate of pCR and tumor
downstaging in the treatment of esophageal cancer. To our knowledge this relationship
in esophageal cancer has never been reported in the literature.

METHODS
Institutional Review Board approved esophagectomy databases at both
institutions were searched to identify patients with esophageal cancers who received CRT
followed by surgical resection. Dates of surgical resections included the time periods of
1994-2006 (TJUH) and 1992-2002 (FCCC). Medical records were reviewed, including
office notes, operative dictations and pathology reports. Data recorded included
demographics, medical history, length of stay, chemotherapeutic regimen, type of
esophagectomy, completeness of resection, histologic diagnosis, tumor location, initial
stage, pathologic stage, pathologic complete response, total lymph nodes, number of
positive lymph nodes, time to recurrence and survival. Patients were classified as having
DM or not based on past medical history as listed in hospital or clinic notes as well as
examination of medication lists (including oral hypoglycemic agents and/or insulin)
during the time that they underwent CRT.
Pretreatment or initial stage was determined using a combination of computed
tomography (CT) scan, endoscopic ultrasound (EUS) and sometimes positron emission
tomography (PET) scans. Staging was by the American Joint Committee on Cancer
(AJCC) TNM staging, sixth edition. The neoadjuvant chemotherapy most often included
a 5-fluoruracil, taxol and platinum (cisplatinum or carboplatinum) regimen, in
concurrence with phase I and II trials at the two institutions 15, 16. These regimens were
most commonly given concurrently with external beam radiation therapy to a dose of 45
Gy. The individual surgical method was left to the discretion of the operating surgeon.
Surgery was performed approximately four to six weeks after the completion of CRT and
re-staging to ensure no metastatic disease. Post-treatment staging was determined by

pathologic review. A pCR was defined as no residual tumor cells in the surgical
specimen including the primary site and surrounding lymph nodes. Downstaging was
defined as patients whose tumors underwent significant regression down to T1 tumors
with no nodal involvement. Chi-square test was used as a comparative analysis of rates
of pathologic complete response rate (pCR) and pathologic downstaging in DM patients
versus non-DM patients.

RESULTS
Two hundred and sixty patients were included in this retrospective study. Thirtysix (13.8%) patients had DM and 224 (86.2%) were nondiabetics (non-DM). The
average age for the overall patient population was 61 years (61 years for DM group
(range=41-78) and 60 years (range=24-84) for non-DM group).

Overall, the male to

female ratio was 5.6:1. Of note, the male to female ratio was 17:1 in the DM group and
5.5:1 in the non-DM group. The location of the tumors was not appreciably different
between the two patient groups. The majority of tumors were located at the distal
esophagus and gastroesophageal junction (Table 1). All patients in both groups
completed neoadjuvant therapy. Surgical resection followed neoadjuvant therapy in all
patients in this study.
The groups did not have statistically different differences in the initial clinical
stage or the pathological stage; the majority of patients in both groups presented with
stage 2 disease. There were 12 patients with initial stage IVa disease. The majority of
stage 2 patients were those with T3N0 disease. Among the non-diabetic patients, there
were 44 with T2, 149 with T3, and 9 with T4 disease. In contrast there were 7 T2, 27 T3,
and one T4 patient in the diabetic group. There were no significant differences in pretreatment nodal staging either with the non-diabetics group having 21% Nx, 36% N0, and
43% N1, and the diabetic group having 27%Nx, 40% N0, and 33% N1.
There were a total of 44 patients with squamous cell carcinoma (SCC, 17%). Of
these 44, only one was diabetic, and this patient did not have a partial or complete
response. Among the 44 patients with SCC, the pCR rate was 32% (14 of 44). A total of
43% of SCC patients achieved a significant partial or complete response. By contrast, the

majority of patients in this series had adenocarcinoma (n=216, 83%) which reflects
national trends. The pCR rate among patients with adenocarcinoma was 25% and the
significant responder rate was 39%.
Among the patients with DM, there were only six patients who required insulin
and the rest (n=30) patients taking oral hypoglycemic agents. Unfortunately due to the
retrospective nature of this study, it is difficult to examine glycemic control. HgA1c
levels were not routinely evaluated and therefore are not available to examine. Most
patients received long-term continuous infusion 5-FU at a dosage of 225 mg/m2/day
during the entire course of radiation therapy. As part of various ongoing clinical trials
many patients received additional chemotherapy agents. These included paclitaxel (doses
ranging from 30 to 60 mg/m2 given weekly), carboplatinum (AUC=5, given on day 1 and
29), and cisplatinum (75mg/m2).
After appropriate neoadjuvant therapy, 19.4% of the diabetic patients and 26.8%
of the nondiabetic patients had no detectable residual disease in the pathologic specimen.
In the diabetic group, 11 patients (30%) had stage 0 or 1 residual disease, while 89 (40%)
of the non-diabetics had stage 0 or 1 residual disease (p= 0.36). In the diabetic group,
33.3% had positive lymph nodes, while in the nondiabetic group 37.7% had positive
lymph nodes (Table 2).
The overall rate of achieving a complete pathologic response for the entire
patient population was 26%. There was a trend for a decrease in the rate of pCR in the
diabetic group, 19% versus 27% in the nondiabetic group. This trend was not statistically
significant (p= 0.31).

Overall, pathologic downstaging occurred in 39% of study patients. The rate of
pathologic downstaging was lower in diabetic patients (33%) compared to nondiabetic
patients (40%), although this was not statistically significant (p= 0.42).

DISCUSSION
Preoperative CRT followed by surgical resection is the treatment regimen
employed in most patients with resectable esophageal cancer. Achieving pCR and node
negative status are two major determinants of outcome following neoadjuvant CRT 14, 17.
Our analysis does not demonstrate a significant difference between diabetic and
nondiabetic patients in terms of achieving pCR and pathologic downstaging. However,
the observed trend does suggest that diabetic patients have an inferior response to
neoadjuvant therapy when compared to nondiabetic patients. In this study, diabetic
patients had a lower rate of both pCR and pathologic downstaging, although neither was
statistically significant. The data reported by Caudle et al, demonstrated that
neoadjuvant therapy was less effective in achieving pCR in diabetic rectal cancer patients
than in their nondiabetic counterparts. Although the exact mechanism remains unknown,
their data, and the data presented in this study, do implicate diabetes as a predictor of
poor response to neoadjuvant therapy 18.

Unlike with colorectal cancers, there is no published data that illustrates a similar
relationship between DM and esophageal cancer 19. There are ample data that support
that diabetes is an independent patient characteristic predictive of increased morbidity
and mortality after esophagectomy 6, 20-22. The incidence of esophageal cancer is
increasing 23 and a large majority of these patients are treated with CRT. Unfortunately
the mortality rate of esophageal cancer remains high. It is therefore of paramount
importance to determine the factors that influence patient response to CRT. The exact
mechanism of the relationship between diabetes and decreased response to CRT remains
unknown. Possible explanations for the negative effect that diabetes has on cancer
patients’ ability to appropriately respond to CRT include the molecular effects of insulin
and insulin-like growth factor on tumor growth, and the relationship between the effects
of DM on the body and the ability to effectively deliver neoadjuvant treatment.
Diabetes mellitus, especially Type II, is often coupled with obesity and
hyperinsulinemia. Hyperinsulinemia is known to cause an increase in insulin-like growth
factor (IGF), a well-studied survival factor for cancer cells. In 2002 Liu et al published
in vitro work showing that IGF, which is upregulated in cancer patients, is able to
stimulate tumor growth. IGF was also shown to prevent the expected apoptosis in
esophageal cancer cells that had been treated with commonly used chemotherapeutic
drugs such as 5-fluorouracil and cisplatin 24. This preclinical work is especially relevant
because hyperinsulinemia and increased levels of IGF in DM and non-DM patients have
been shown to be a risk factor for developing gastroesophageal adenocarcinoma as well
as other gastrointestinal cancers 25, 26. In this retrospective study we did not measure
insulin or IGF levels in our patients or in their tumor specimens. Future prospective

clinical studies that include this information have the potential to clarify the relationship
between DM, hyperinsulinemia, IGF levels and response to neoadjuvant therapy.
A more tangible yet hypothetical possibility to explain the relationship between
DM and patient response to neoadjuvant therapy is the long-term effect that diabetes has
on patients’ microvasculature. The relative hypoxic environment created by vascular
disease may reduce the effectiveness of radiation therapy. Additionally, the
compromised blood flow could limit the delivery of chemotherapy. DM contributes to
the development of microvascular disease as has been shown by multiple studies to
contribute to morbidity and mortality in patients undergoing esophagectomy 6, 20-22. The
complications caused by microvasculature disease could also lead to decreased delivery
of radiosensitizing drugs. This may compound the hypoxic environment of the tumor and
diminish the efficacy of radiation therapy. For example, microvascular disease is felt to
contribute to the higher rate of anastomotic leak seen in diabetic patients after rectal
surgery 27. Additionally, in cervical cancer, rectal dysfunction is increased in diabetic
patients after radiotherapy in comparison to non-diabetics28. These functional
consequences may help to explain the role of microvascular disease in the decreased drug
delivery to the tumor and therefore a decreased response to therapy.
There are numerous factors that will need to be further studied as we attempt to
elucidate this relationship. If increased insulin levels do indeed promote tumor growth,
then it would seem important that glucose levels be tightly controlled during neoadjuvant
therapy. Due to the retrospective nature of this study, HbA1c levels were not routinely
followed in these patients. Also, patients undergoing neoadjuvant therapy for esophageal
cancer often have severe dysphagia at the commencement of therapy and will have

derangements in their diet—either decreased calories or an increased carbohydrate load
in those patients receiving jejunostomy tube feeds. These serve to cause wide
fluctuations in glucose and insulin levels. Prospective study of these phenomena will be
important.
The results of this study suggest diabetic patients with esophageal cancer have a
decreased ability to respond to CRT. This is the first study which demonstrates that there
could be a relationship between diabetes mellitus and response to neoadjuvant
chemoradiation; this study raises a hypothesis that warrants future investigations with a
larger patient population.
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TABLE 1—Demographics

Total number
Average age
Gender (male:female
ratio)
Location of tumor
Proximal
Middle
Distal
GE Junction
Cardia
Surgical Procedure
Ivor-Lewis
Transhiatal

Diabetic Patients

Nondiabetic Patients

36
61 (range 41-78)
17:1

224
60 (range 24-84)
5.5:1

0 (0%)
2 (5.6%)
16 (44.4%)
14 (38.9%)
4 (11.1%)

2 (0.9%)
26 (11.6 %)
92 (41%)
84 (37.5%)
20 (8.9%)

19 (52.8%)
8 (22.2%)

107 (47.8%)
46 (20.5%)

3-Hole
Other

5 (13.9%)
4 (11.1%)

62 (27.7%)
9 (4.0%)

TABLE 2—Patient Staging

Initial clinical
Stage*
1
2
3
4
Pathologic Stage
No Residual
Disease
1

2
3
4
Positive lymph
node status**

Diabetic Patients
(n=36)

Nondiabetic Patients
(n=224)

0 (0%)
21 (61.8%)
11 (32.4%)
2 (5.9%)

2 (0.96%)
124 (59.6%)
72 (34.6%)
10 (4.8%)

7 (19.4%)

60 (26.8%)

4 (11.1%)

29 (13.0%)

14 (38.9%)
10 (27.8%)
1 (2.8%)
12 (33.3%)

72 (32.1%)
49 (21.9%)
14 (6.3%)
83 (37.7%)

* Data unavailable for 2 diabetic and 16 nondiabetic patients
** Data unavailable for 4 nondiabetic patients

TABLE 3—Response to chemoradiotherapy
Diabetic Patients
(n=36)

Nondiabetic Patients
(n=224)

p value

pCR*

7/36 (19.4%)

60/223 (27%)

0.42

Pathologic
downstaging

12/36 (33%)

90/224 (40%)

0.47

* Data unavailable for 1 nondiabetic patient

